

# JosÃ© Miguel Rivera Caravaca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7416540/publications.pdf>

Version: 2024-02-01

103  
papers

1,564  
citations

331538

21  
h-index

360920

35  
g-index

105  
all docs

105  
docs citations

105  
times ranked

1850  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. <i>Journal of General Internal Medicine</i> , 2023, 38, 315-323.	1.3	2
2	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes" A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	1.8	219
3	Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. <i>Europace</i> , 2022, 24, 4-11.	0.7	2
4	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs clinical-trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 282-289.	1.1	8
5	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.	0.7	9
6	Novel insights in the relationship of gut microbiota and coronary artery diseases. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 3738-3750.	5.4	14
7	Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, 111, 1040-1047.	1.5	6
8	Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109215.	1.1	0
9	Growth Differentiation Factor 15 in Cardiovascular Diseases: Predicting Bleeding after Cardiac Surgery and Beyond That!. <i>Thrombosis and Haemostasis</i> , 2022, 122, 657-660.	1.8	2
10	Occupational Therapy in Severe Mental Disorder" A Self-Controlled Quasi-Experimental Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 493.	1.0	1
11	Relation of the "Atrial Fibrillation Better Care (ABC) Pathway"™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.	1.1	4
12	Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13788.	1.7	5
13	Stress in Emergency Healthcare Professionals: The Stress Factors and Manifestations Scale. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4342.	1.2	6
14	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. <i>European Journal of Internal Medicine</i> , 2022, 98, 122-124.	1.0	1
15	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
16	Predicting heart failure in atrial fibrillation patients: What about using biomarkers?. <i>American Heart Journal</i> , 2022, 251, 32-32.	1.2	0
17	Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.	0.8	1
18	Incident arrhythmias, heart failure and cardiovascular outcomes with SGLT-2 inhibitor use in diabetic patients: Insights from a global federated electronic medical record database. <i>Europace</i> , 2022, 24, .	0.7	0

#	ARTICLE	IF	CITATIONS
19	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1107-1114.	1.8	4
20	Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13436.	1.7	45
21	Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs real-world. <i>International Journal of Clinical Practice</i> , 2021, 75, e13888.	0.8	1
22	Experiencia de 7 años con la protesis aortica de rpido despliegue Edwards Intuity. <i>Cirugia Cardiovascular</i> , 2021, 28, 77-83.	0.1	0
23	Novel biomarkers in Alzheimer's disease using high resolution proteomics and metabolomics: miRNAs, proteins and metabolites. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 167-179.	2.7	9
24	Comparison of Aortic Gradient and Ventricular Mass after Valve Replacement for Aortic Stenosis with Rapid Deployment, Sutureless, and Conventional Bioprostheses. <i>Cardiology</i> , 2021, 146, 656-666.	0.6	2
25	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 715.	1.0	9
26	Should we make the risk stratification process more complex in patients with atrial fibrillation?. <i>Europace</i> , 2021, 23, 978-978.	0.7	1
27	Validating scores predicting atrial fibrillation recurrence post catheter ablation in patients with concurrent atrial fibrillation and pulmonary diseases. <i>Annals of Palliative Medicine</i> , 2021, 10, 4299-4307.	0.5	3
28	Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. <i>Thrombosis Research</i> , 2021, 205, 1-7.	0.8	18
29	Relationship between sleep habits and academic performance in university Nursing students. <i>BMC Nursing</i> , 2021, 20, 100.	0.9	14
30	Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 330-339.	1.8	63
31	Mid-term outcomes of rapid deployment aortic prostheses in patients with small aortic annulus. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 695-701.	0.5	3
32	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. <i>Journal of Clinical Medicine</i> , 2021, 10, 3357.	1.0	4
33	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7113.	1.8	7
34	Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. <i>Cardiovascular Diabetology</i> , 2021, 20, 176.	2.7	10
35	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021, 153, 111482.	1.2	16
36	Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP Long-term General Registry. <i>European Journal of Clinical Investigation</i> , 2021, , e13709.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787235.	1.1	4
38	Short- and medium-term complications after emergency department treatment of patients with atrial fibrillation: design and internal validation of the CoSTuM risk scale. <i>Emergencias</i> , 2021, 33, 85-92.	0.6	0
39	Effectiveness of music therapy and progressive muscle relaxation in reducing stress before exams and improving academic performance in Nursing students: A randomized trial. <i>Nurse Education Today</i> , 2020, 84, 104217.	1.4	31
40	One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1052-1061.	1.1	7
41	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1867-1881.	0.9	3
42	Letter by Ding et al Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation". <i>Stroke</i> , 2020, 51, e361-e362.	1.0	0
43	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3645.	1.0	11
44	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 331-345.	0.4	0
45	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.	0.8	13
46	The COVID-19 Pandemic and Its Impact on Homebound Nursing Students. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7383.	1.2	74
47	Work Shift and Circadian Rhythm as Risk Factors for Poor Sleep Quality in Public Workers from Murcia (Spain). <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5881.	1.2	6
48	Reliability and Validity of a Stress Scale in Public Employees from Murcia (Spain). <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8894.	1.2	2
49	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2360-2369.	1.4	8
50	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1200-1207.	1.8	41
51	Influence of the matrix type over the concentration of GDF-15. <i>Journal of Investigative Medicine</i> , 2020, 68, 1402-1404.	0.7	0
52	A new tool to assess patients'™ comfort during hospitalization: The Hospital Discomfort Risk questionnaire. <i>Journal of Nursing Management</i> , 2019, 27, 1485-1491.	1.4	2
53	Incidence and causes of pacemaker implantation during postoperative period of aortic valve replacement with rapid deployment prosthesis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1534-1540.	0.5	3
54	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1901-1919.	1.8	57

#	ARTICLE	IF	CITATIONS
55	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019, 50, 1372-1379.	1.0	48
56	Galectin-3 and Î²-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. <i>Scientific Reports</i> , 2019, 9, 6235.	1.6	1
57	ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists. <i>REC: CardioClinics</i> , 2019, 54, 165-172.	0.1	3
58	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
59	Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1891-1893.	1.8	5
60	Chronic Kidney Disease and Third-Generation P2Y <sub>12</sub> Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 295-302.	1.0	2
61	Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. <i>European Journal of Internal Medicine</i> , 2019, 61, 48-53.	1.0	19
62	EpidemiologÃa del mixoma cardiaco en una poblaciÃ³n espaÃ±ola. Una serie quirÃºrgica de 30 aÃ±os. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 685-686.	0.6	0
63	Switching of Oral P2Y <sub>12</sub> Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis. <i>Clinical Drug Investigation</i> , 2019, 39, 275-283.	1.1	1
64	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 183-188.	0.2	3
65	Epidemiology of Cardiac Myxoma in a Spanish Population. A 30-year Surgical Series. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 685-686.	0.4	2
66	Riesgo embÃ³lico, riesgo isquÃ©mico y riesgo hemorrÃ¡gico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019, 18, 3-8.	0.2	0
67	Reliability and validity of the student stress inventory-stress manifestations questionnaire and its association with personal and academic factors in university students. <i>Nurse Education Today</i> , 2018, 64, 156-160.	1.4	27
68	Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices. <i>European Journal of Internal Medicine</i> , 2018, 52, 54-59.	1.0	8
69	Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft-Gault, Modification of Diet in Renal Disease-4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	16
70	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12929.	1.7	5
71	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018, 72, e13069.	0.8	4
72	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 892-902.	1.1	66

#	ARTICLE	IF	CITATIONS
73	Quality of oral anticoagulation with vitamin K antagonists in "real-world"™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018, 20, 1435-1441.	0.7	39
74	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIA Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 279-287.	1.8	17
75	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018, 40, 114-122.	1.1	21
76	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1065-1073.	1.4	28
77	Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation. <i>Circulation Journal</i> , 2018, 82, 353-360.	0.7	5
78	Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Hematology</i> , 2018, 23, 712-718.	0.7	0
79	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. <i>Journal of General Internal Medicine</i> , 2018, 33, 847-854.	1.3	14
80	Enhancing the "real world"™ prediction of cardiovascular events and major bleeding with the CHA <sub>2</sub> DS <sub>2</sub> -VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018, 50, 26-34.	1.5	22
81	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in "real-world"™ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. <i>International Journal of Cardiology</i> , 2018, 254, 125-131.	0.8	18
82	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA <sub>2</sub> DS <sub>2</sub> -VASc and HAS-BLED. <i>American Heart Journal</i> , 2018, 197, 27-34.	1.2	8
83	Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 57-65.	1.0	21
84	Risk factors for mental workload: influence of the working environment, cardiovascular health and lifestyle. A cross-sectional study. <i>BMJ Open</i> , 2018, 8, e022255.	0.8	3
85	Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007264.	1.4	2
86	Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines. <i>PLoS ONE</i> , 2018, 13, e0208069.	1.1	4
87	Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores. <i>Journal of the American Heart Association</i> , 2018, 7, e009766.	1.6	23
88	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.	0.7	4
89	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World"™ in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792.	0.7	12
90	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017, 7, 41565.	1.6	31

#	ARTICLE	IF	CITATIONS
91	Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. <i>European Journal of Cardiovascular Nursing</i> , 2017, 16, 696-703.	0.4	10
92	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 2176-2181.	0.7	19
93	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. <i>American Journal of Hypertension</i> , 2017, 30, 1063-1065.	1.0	13
94	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 12066.	1.6	16
95	Long-term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA <sub>2</sub> DS <sub>2</sub> -VASc Scores. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
96	Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation. <i>Evidence-Based Medicine</i> , 2017, 22, 154-155.	0.6	2
97	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1051-1062.	1.0	24
98	Applicability of the modified CHA <sub>2</sub> DS <sub>2</sub> -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017, 38, e21-e22.	1.0	5
99	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. <i>Biological Research for Nursing</i> , 2017, 19, 198-205.	1.0	1
100	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1448-1454.	1.8	74
101	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2261-2266.	1.8	51
102	Long-term bleeding risk prediction in "real world" patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1848-1858.	1.8	56
103	Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. <i>Oncotarget</i> , 2017, 8, 80182-80191.	0.8	12